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Vaccination of neonatal calves with Mycobacterium bovis bacillus Calmette-Gue´rin (BCG) induces a signif-
icant degree of protection against infection with virulent M. bovis, the causative agent of bovine tuberculosis
(bTB). We compared two strains of BCG, Pasteur and Danish, in order to confirm that the current European
human vaccine strain (BCG Danish) induced protective immunity in calves, and we assessed immune re-
sponses to determine correlates of protection that could assist future vaccine evaluation in cattle. Both vaccine
strains induced antigen (purified protein derivate [PPD])-specific gamma interferon (IFN-) in whole-blood
cultures. These responses were not significantly different for BCG Pasteur and BCG Danish and peaked at
week 2 to 4 postvaccination. Vaccination with either BCG Danish or BCG Pasteur induced significant
protection against bTB, with reductions in both lesion score and bacteriological burden evident in both groups
of vaccinated calves compared with nonvaccinated control calves. Measurement of IFN--expressing T lym-
phocytes postvaccination and postchallenge revealed both correlates and surrogates of protective efficacy. The
frequency of central memory T lymphocytes present at 12 weeks postvaccination (at the time of M. bovis
challenge) correlated significantly with protection. Conversely, the number of IFN--expressing effector T cells
present after M. bovis challenge was correlated with disease. These results demonstrate that vaccination of
neonatal calves with either BCG Pasteur or BCG Danish induces protective immune responses against TB. In
addition, we show that measurement of antigen-specific T lymphocyte populations may provide a reliable
means for identifying protective vaccine candidates.
The persistence and/or increasing incidence of bovine tuber-
culosis (bTB) poses a human health risk and a major economic
problem in developed countries, including the United King-
dom, the United States, and New Zealand. One potential con-
trol strategy is vaccination: numerous studies have been per-
formed to generate, validate, and test the potential efficacy of
TB vaccines (1, 21, 32). The live attenuated Mycobacterium
bovis strain bacillus Calmette-Gue´rin (BCG) has been shown
to have variable efficacy against TB in humans and cattle (6,
14). More recently, the optimization of the use of BCG for
cattle and the application of alternative vaccination strategies
such as neonatal vaccination (20, 24, 31) and heterologous
prime-boost vaccination (13, 25, 26, 35, 36), have significantly
improved the efficacy of BCG. Although a major constraint on
the use of BCG as a vaccine in cattle is that it interferes with
detection of bTB by tuberculin-based skin test and gamma
interferon (IFN-) detection methods, diagnostic tests utilizing
M. bovis-specific antigens are being developed (3, 5, 11, 34, 37).
Neonatal BCG vaccination of humans and cattle is associ-
ated with Th1-biased immune responses which may be critical
for protective immunity. We and others have previously dem-
onstrated that BCG vaccination of calves within the first weeks
of life is associated with partial protection against challenge
with virulent M. bovis and that protection is associated with
antigen-specific IFN- secretion (2, 8, 20). The focus of this
study was to provide additional information on the compara-
tive protective efficacy of neonatal vaccination of cattle with
the BCG strain licensed for humans in the United Kingdom,
BCG Danish SSI, and BCG Pasteur. In previous studies (39),
BCG Danish vaccination of calves was shown to induce poor
IFN- responses but nevertheless induced a significant level of
protective immunity against M. bovis challenge.
Here we have also assessed the potential for immunolog-
ical measurements to provide correlates of BCG-induced
protective immunity. Defining correlates of immunity can
assist in the development of novel vaccines and vaccination
strategies. Mechanisms to predict vaccine efficacy enable
prioritization of vaccines for further study in experimental
challenge studies. For cattle (and nonhuman primate) stud-
ies, where costs are relatively high and there are few suitable
containment facilities, defining correlates which can be used
to minimize the number of potential vaccine candidates is
essential. We demonstrate that BCG Pasteur and BCG Dan-
ish induce similar levels of protective immunity in neonatal
calves and that measurement of BCG vaccine-induced IFN-
-expressing memory T lymphocytes could help predict vac-
cine efficacy.
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Compton, Newbury, Berkshire RG20 7NN, United Kingdom. Phone:
01635-577239. Fax: 01635-577263. E-mail: jayne.hope@BBSRC.ac.uk.
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MATERIALS AND METHODS
Bacteria and calf inoculations. BCG Pasteur (P2; sourced from Veterinary
Laboratories Agency, Weybridge) was diluted from previously titrated frozen
(70°C) stock grown in Middlebrook 7H9 broth containing 10% ADC supple-
ment (19). Calves were inoculated with 2 ml BCG Pasteur subcutaneously (20).
BCG Danish (batch number 104028A) was purchased from Statens Serum In-
stitute, Denmark, and reconstituted from lyophilized vials in the supplied diluent
according to the manufacturers’ instructions (Sauton medium). Calves were
inoculated subcutaneously with 0.5 ml of BCG Danish (5 times the recom-
mended human dose). For each batch of BCG, the titer was assessed within 1 h
of reconstitution/thawing by titration on 7H10 agar. The BCG dose was approx-
imately 2  106 CFU per calf for both vaccines.
For challenge, M. bovis (strain AF 2122/97 [16]) was diluted immediately prior
to inoculation from frozen stock in 7H9 medium. Cattle were inoculated intra-
tracheally as previously described (36). The dose of M. bovis was confirmed by
titration on modified 7H11 agar plates (15) as approximately 3  103 per calf.
Animals and experimental plan. Cattle were British Holstein-Friesian calves
(Bos taurus) bred at the Institute for Animal Health. The IAH herd has been
confirmed free from bovine TB for more than 10 years. Animals were vaccinated
with BCG at between 1 day and 27 days of age. Control animals were not
vaccinated. Seven calves were assigned to each group according to age. Twelve
weeks following vaccination, calves were transferred into a high-security ACDP
category 3 animal housing unit and infected with M. bovis via the intratracheal
route. Twelve weeks following infection, tuberculin skin tests were performed.
The animals were killed 1 week later and postmortem examinations performed
as described below. The experiments were approved by the local ethics commit-
tee according to United Kingdom national guidelines.
Postmortem examination and bacteriology. Lymph nodes of the head (retro-
pharyngeal, submandibular, and parotid) and thorax (mediastinal and four bron-
chus associated), tonsils, nasal, and tracheal mucosa and the seven pulmonary
lobes were examined for gross lesions following the cutting of 0.5- to 1-cm slices.
Macroscopic lesions were scored as previously described (33). Tissues were fixed
in 10% formal saline and processed for histological examination following stain-
ing with hematoxylin and eosin. Tissues with typical lesions of TB evident by
microscopy, but no gross lesions, were given a score of 1 in the overall pathology
comparison. Tissue samples were frozen at70°C for subsequent bacteriological
examination by titration of tissue homogenates on modified 7H11 agar (15).
Antigens. Purified protein derivatives from Mycobacterium avium (PPD-A)
and M. bovis (PPD-B) were obtained from the tuberculin production unit at
Veterinary Laboratories Agency (VLA), Weybridge. Recombinant ESAT-6 and
CFP-10 were as described previously (11). These antigens are expressed by M.
bovis but not by BCG and are used to discriminate between infected and vacci-
nated individuals.
Tuberculin skin tests. The single comparative intradermal tuberculin test with
avian and bovine PPD (PPD-A and PPD-B, respectively) was by intradermal
inoculation of 0.1 ml of PPD-A and PPD-B, and reactions were read 72 h later.
Results were recorded as increase in skin thickness at 72 h compared to thickness
preinjection and interpreted according to the standard protocol (European Com-
munities Commission regulation number 1226/2002) (27).
Immunological assays. Blood was collected into heparin (10 U/ml). For cyto-
kine assays, 4-ml aliquots of blood were incubated at 37°C for 24 h with PPD-A
or PPD-B (final concentration of 20 g per ml) diluted in RPMI with 50 g/ml
gentamicin. ESAT-6 and CFP-10 were used at a final concentration of 5 g/ml.
An equal volume of RPMI with gentamicin was used as a control. The super-
natant was removed after centrifugation and stored at 20°C until assayed.
IFN- was assayed by enzyme-linked immunosorbent assay (ELISA) as de-
scribed previously, using recombinant bovine IFN- as a standard (23). Each
sample assayed was measured in duplicate by ELISA; the variability between
samples was less than 5%.
ELISPOT assay. Secretion of IFN- by cultured peripheral blood mononu-
clear cells (PBMC) was also assessed by enzyme-linked immunospot (ELISPOT)
assay (20, 41). For the cultured ELISPOT assay (40), PBMC were prepared and
stimulated in 24-well plates (2  106 PBMC/ml; 1-ml aliquots) with PPD-B at 10
g/ml. PBMC cultures were fed on days 5 and 8 with recombinant bovine
interleukin-2 (IL-2) (final concentration, 10 U/ml). On days 10 and 12, half of the
supernatant was removed and replaced with tissue culture medium without IL-2.
Cells were washed four times on day 13 by centrifugation and counted, and 104
cells were added to wells of ELISPOT plates (20) and cultured together with
antigen (PPD-A and PPD-B; 10 g/ml). To each well, 1  103 autologous
monocyte-derived dendritic cells (19) were added. Cells were cultured for 24 h,
and spots were developed (20, 41). Results are expressed as spot-forming cells
(SFC) per 106 PBMC.
Cytokine flow cytometry (CFC). Whole-blood samples were incubated for 20
to 24 h at 37°C with 10 g/ml PPD-B or an appropriate volume of phosphate-
buffered saline (PBS) as a control. For the final 4 h of the incubation period, 10
g/ml brefeldin A (BFA) was added. The expression of CD4 and intracellular
IFN- was assessed as previously described (29). The cells were assayed using a
flow cytometer (FACSCalibur; Becton Dickinson), and the data were analyzed
using FCS Express (De Novo Software, Ontario, Canada). A minimum of 50,000
events were collected. The mononuclear cells were identified by light-scattering
properties, and the percentages of CD4 cells that expressed IFN- were cal-
culated.
Statistical analyses. Analyses were performed using MINITAB. Differences in
immunological responses, degree of pathology, and bacterial colonization be-
tween BCG-vaccinated and control calves were compared using the Mann-
Whitney test. P values of 0.05 were considered significant.
RESULTS
Vaccination with BCG Pasteur or BCG Danish in neonatal
calves induces comparable levels of protection against disease
caused by M. bovis challenge. One group of neonatal calves was
vaccinated with BCG Pasteur and one group with BCG Dan-
ish. A third group of calves was inoculated with medium.
Twelve weeks after BCG vaccination, calves were challenged
intratracheally with M. bovis; the degree of protection afforded
by each strain of BCG compared to nonvaccinated controls
was assessed at 12 weeks postchallenge (Tables 1 and 2). None
TABLE 1. Lesions at necropsy 12 weeks after M. bovis challenge in
BCG-vaccinated and control animals
Vaccination and
animal no.
Total lesion scorea
Lymph nodesb Lungc
BCG Pasteur
105 0 0
109 10 8
118 0 5
123 1 0
129 0 2
134 2 0
137 0 0
Median 0** 0*
BCG Danish
104 5 3
113 0 4
117 2 3
127 4 6
130 5 3
133 2 3
138 3 8
Median 3** 3*
Control M. bovis alone
101 11 7
103 16 10
106 8 8
108 6 10
128 4 6
131 13 6
135 11 5
Median 11 7
a , P 0.01 compared to control M. bovis-alone group; , P 0.05 compared
to control M. bovis-alone group.
b Total lesion score for head lymph nodes (left and right parotid, submandib-
ular, retropharyngeal, and tonsil) and respiratory tract-associated lymph nodes
(mediastinal and four bronchial nodes).
c Total lesion score for seven lung lobes (left and right apical, medial, dia-
phragmatic, and intermediate).
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of the animals showed clinical signs of disease (anorexia, poor
responsiveness, rapid or difficult breathing, or coughing). Le-
sions typical of TB were observed in all of the nonvaccinated
control animals, in both lymph nodes and lung. Although the
extent of lesions varied between animals, as reflected by the
lesion scores (Table 1), in each case lesions were primarily
restricted to the respiratory tract-associated lymph nodes and
lungs. One control animal (no. 135) had a single lesion in the
right submandibular lymph node. Both BCG Danish and BCG
Pasteur conferred significant protection against disease, with
reduced lesion scores noted in lymph nodes (P  0.01) and
lung (P  0.05). This reflects both reduced number and size of
TB lesions in vaccinated animals. There was no significant
difference in the level of protection induced by BCG Danish
versus BCG Pasteur.
BCG vaccination of neonatal calves reduces the level of
bacterial colonization. Bacteriological examination of tissues
indicated that M. bovis was present in numbers of up to 7 104
CFU per gram from the majority of tissues with gross lesions
(Table 2), with a significant correlation between the number of
isolated bacteria and lesion score (P  0.05; data not shown).
Overall, significantly fewer bacteria were isolated from tissues
from both the BCG Danish- and BCG Pasteur-vaccinated
groups than from the control group (P 0.05). However, when
bacterial numbers in lymph nodes and lung were analyzed
separately, differences between the vaccines were observed. A
significant reduction in CFU was observed in the lymph nodes
of calves vaccinated with BCG Danish and BCG Pasteur (P 
0.05), whereas BCG Pasteur induced significantly greater pro-
tection in lung tissue (P  0.05).
Skin test reactivity in BCG-vaccinated and control calves
following M. bovis challenge. Reactions to PPD in the skin test
were observed in all animals at 12 weeks after challenge with
M. bovis (Table 3). Visible local clinical signs and increases in
comparative skin thickness (skin test thickness response with
PPD-B minus that with PPD-A) ranging from 8 to 30 mm were
recorded. Low responses to PPD-A were noted, and all ani-
mals would be classified as reactors according to the standard
interpretation of the skin test (European Communities Com-
mission regulation number 1226/2002) (27). There were no
significant differences between any of the groups.
BCG Danish and BCG Pasteur induce similar kinetics and
intensity of antigen-specific IFN- responses in whole-blood
cultures. Immune responses were monitored for 12 weeks in
nonvaccinated control (Fig. 1a), BCG Pasteur-vaccinated (Fig.
1b), and BCG Danish-vaccinated (Fig. 1c) calves. At 12 weeks
the calves were infected with M. bovis, and immune responses
were monitored for an additional 12 weeks (the time of chal-
TABLE 2. M. bovis viable counts in tissues taken postmortem from
BCG-vaccinated and control animals
Vaccination and
animal no.
Total bacterial count (log10 CFU)a
Lymph nodesb Lungc
BCG Pasteur
105 2.9 ND
109 4.6 3.5
118 4.2 3.5
123 4.3 ND
129 2.8 ND
134 4 ND
137 2.1 ND
Median 4.04** 0*
BCG Danish
104 4.6 4.4
113 4.3 2.3
117 4.3 3.4
127 4.1 3.7
130 4.6 1.7
133 4 3.2
138 4.2 3.5
Median 4.26* 3.39
Control M. bovis alone
101 4.8 4.2
103 4.8 3.7
106 5.2 3.1
108 5 4
128 4.2 4.5
131 4.6 4.3
135 4.8 3.6
Median 4.78 3.96
a Viable counts were recorded as log10 CFU per gram tissue. ND, not detected
(below sensitivity limit of 5 CFU). , P  0.01 compared to control M.
bovis-alone group; , P  0.05 compared to control M. bovis-alone group.
b Total log10 CFU for head lymph nodes (left and right parotid, submandib-
ular, retropharyngeal, and tonsil) and respiratory tract-associated lymph nodes
(mediastinal and four bronchial nodes).
c Total log10 CFU for seven lung lobes (left and right apical, medial, diaphrag-
matic, and intermediate).
TABLE 3. Tuberculin skin test responses
Vaccination and
animal no.
Increase (mm)a
PPD-A PPD-B PPD-B PPD-A
BCG Pasteur
105 3 16 13
109 8 34 26
118 5 17 12
123 5 28 23
129 6 23 17
134 6 27 21
137 4 16 12
Mean 17.1
BCG Danish
104 5 28 23
113 3 12 9
117 2 19 17
127 5 28 23
130 6 31 25
133 NT NT NT
138 4 29 25
Mean 21
Control M. bovis alone
101 4 33 29
103 4 28 24
106 1 9 8
108 4 26 22
128 5 28 23
131 6 26 20
135 6 36 30
Mean 22.3
a Increase in skin thickness from day 0 to day 3. No significant differences
between groups were noted, and all animals were classed as reactors according
to the standard interpretation of the test. NT, not tested.
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lenge is indicated by an arrow). Significant increases in PPD-
B-specific IFN- secretion in response to vaccination with both
BCG Pasteur (Fig. 1b) and BCG Danish (Fig. 1c) were evident
as early as 2 weeks postvaccination (P 0.05). The peak IFN-
response to BCG was detected between 2 and 4 weeks post-
vaccination, and this had waned significantly by week 12 (P 
0.05). There were no significant differences detected between
animals vaccinated with BCG Pasteur and those vaccinated
with BCG Danish at any time point postvaccination. No sig-
nificant PPD-B-specific IFN- was detected in the control
group prior to M. bovis challenge at week 12 (Fig. 1a). There
was no significant correlation between the overall IFN- pro-
duced during the 12-week vaccination period and the extent of
protection against disease as assessed by lesion score (r2 
0.115). Responses postvaccination to ESAT-6 and CFP-10
were absent or very low and intermittent (200 pg/ml at any
time [data not shown]).
After challenge with M. bovis, a rapid induction of PPD-B-
specific IFN- was observed in both vaccinated groups. Two
weeks following challenge (week 14), PPD-B-specific re-
sponses were elevated in vaccinated calves (Fig. 1b and c) and
were significantly higher than those in control calves (Fig. 1a)
(P 0.05). By week 4 postchallenge (Fig. 1, week 16), all calves
displayed strong IFN- responses, and no significant differ-
ences were detected between groups from this point on. No
significant differences in PPD-B-specific IFN- secretion be-
tween BCG Danish-vaccinated and BCG Pasteur-vaccinated
groups were noted at any time point throughout the time
period. Reactivity to ESAT-6 and CFP-10 was detected in all
animals by week 4 postchallenge (Fig. 1d, week 16) but was
significantly lower in all BCG-vaccinated animals than in non-
vaccinated animals (P  0.05). Animals vaccinated with BCG
Pasteur also had significantly lower ESAT-6/CFP-10 responses
than nonvaccinated animals at weeks 20 and 24 (Fig. 1d) (P 
0.01). The total ESAT-6/CFP10-specific IFN- measured post-
challenge correlated with lesion score (r2  0.78; P  0.001).
No significant differences between BCG Pasteur or BCG Dan-
ish groups were noted at any time point after M. bovis chal-
lenge.
The frequency of antigen-specific IFN--secreting memory
cells induced postvaccination correlates with protective immu-
nity. At 12 weeks postvaccination, immediately prior to M.
bovis challenge, PBMC were isolated from all calves and cul-
tured in the presence of antigen and IL-2 to establish short-
term T cell lines. Following 2 weeks of culture, the presence of
memory T cells secreting IFN- was assessed by ELISPOT
assay. The frequency of PPD-B-specific SFC (PPD-B minus
PPD-A) was calculated (Fig. 2a). Vaccination of cattle with
either BCG Danish or BCG Pasteur (Fig. 2a, closed symbols)
induced IFN--expressing central memory T lymphocytes, and
these were significantly higher than those observed in non-
vaccinated animals (Fig. 2a, open symbols) at the same time
point (P  0.05). The number of central memory lymphocytes
present at the time of M. bovis challenge (week 12 post-BCG)
FIG. 1. Secretion of antigen-specific IFN- in whole-blood cultures. (a to c) Levels of IFN- released from bovine whole-blood cultures
stimulated with PPD-A, PPD-B, or medium from nonvaccinated controls challenged with M. bovis at week 12 (arrow) (a), animals vaccinated with
BCG Pasteur at week 0 and challenged with M. bovis at week 12 (b), or animals vaccinated with BCG Danish at week 0 and challenged with M.
bovis at week 12 (c). (d) Whole-blood IFN- responses to stimulation with ESAT-6/CFP-10 cocktail were measured after M. bovis challenge in
control calves, BCG Pasteur-vaccinated calves, and BCG Danish-vaccinated calves. IFN- levels are expressed as group mean values ( standard
deviation [SD]) for plasma concentrations (pg/ml). *, P 0.05; **, P 0.01 (compared to nonvaccinated control group). No significant differences
were observed between vaccines.
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was negatively correlated with the severity of disease, as as-
sessed by lesion score (Pearson correlation, 0.794; P 
0.0001).
By subdividing the groups of animals into nonvaccinated
control animals (C), vaccinated/protected animals (P), and
vaccinated/unprotected animals (NP) as previously described
(36), 11 animals were defined as protected (lesion score of less
than 10) and 3 as not protected (lesion score of greater than
10). Assessment of the cultured ELISPOT responses showed
that the vaccinated/protected animals had significantly (P 
0.05) higher responses postvaccination than the vaccinated/
unprotected animals, which had cultured ELISPOT responses
similar to those of the control group (Fig. 2b). Thus, higher
numbers of central memory cells were associated with protec-
tive immunity induced by BCG.
The frequency of antigen-specific IFN--secreting CD4 T
cells induced postchallenge is a surrogate for protective im-
munity. At 12 weeks after M. bovis challenge, the percentage of
CD4 T lymphocytes expressing IFN- in response to PPD-B
stimulation of whole blood was measured (Fig. 2c). The fre-
quency of CD4 T lymphocytes expressing PPD-B-specific
IFN- was significantly higher in animals that were not vacci-
nated with BCG prior to M. bovis infection (Fig. 2c, open
symbols) than in those which were previously BCG vaccinated
(Fig. 2c, closed symbols) (P  0.05). The number of IFN--
expressing antigen-specific CD4 T lymphocytes correlated
with the severity of disease; those animals with high lesion
scores had elevated numbers of antigen-specific IFN--ex-
pressing lymphocytes (Pearson correlation, 0.838; P  0.0001).
The vaccinated/protected animals had significantly lower num-
bers of IFN--expressing CD4 T cells (Fig. 2d) than both the
control animals (P  0.001) and the vaccinated/unprotected
animals (P  0.05).
DISCUSSION
Vaccination of neonatal calves with BCG Pasteur has been
demonstrated to induce significant protection against experi-
mental challenge with virulent M. bovis (2, 8, 20). However, of
the available daughter strains of BCG, only commercially pro-
duced BCG Danish is licensed for use in humans in the United
Kingdom. The focus of this study was therefore to provide
additional information on the comparative protective efficacies
of neonatal vaccination of cattle with the human BCG Danish
vaccine strain (SSI) and BCG Pasteur.
Vaccination with either BCG Pasteur or BCG Danish sig-
nificantly reduced the lesion score after M. bovis challenge, and
no significant differences between vaccines were noted. Similar
protective efficacies of BCG Danish and BCG Pasteur were
reported in other studies of M. bovis infection in cattle (39) and
in white-tailed deer (28) and for protection against Mycobac-
terium tuberculosis infection in mice (10). Some differences
FIG. 2. The frequency of antigen-specific IFN--secreting T lymphocytes correlates with protective immunity. (a) At 12 weeks after BCG
vaccination, memory cell responses were assessed by cultured ELISPOT assay. The number of PPD-B-specific IFN- SFC induced by vaccination
(black circles) or in control calves (white circles) correlates with protection against TB as determined by lesion score. (b) Cultured ELISPOT
responses in relation to vaccine success (vaccinated/protected, P) or failure (vaccinated/unprotected, NP). C, nonvaccinated controls. (c) At 12
weeks after M. bovis challenge, the capacity for CD4 T cells to express PPD-B-specific IFN- was assessed by flow cytometric analysis. The number
of CD4 T cells expressing PPD-B-specific IFN- was assessed for vaccinated (black circles) and control calves (white circles). (d) Number of
CD4 T cells expressing IFN- in flow cytometric analysis in relation to vaccine success (vaccinated/protected, P) or failure (vaccinated/
unprotected, NP). C, nonvaccinated controls. *, P  0.05; **, P  0.01; ***, P  0.001.
VOL. 18, 2011 PROTECTIVE IMMUNE RESPONSES AGAINST TB IN CALVES 377
were observed between vaccines in terms of reduction of bac-
terial colonization: commercially produced BCG Danish ap-
peared to be less effective in controlling M. bovis growth in the
lungs than laboratory-grown BCG Pasteur. This contrasts with
previously published data which showed that BCG Danish was
more effective than BCG Pasteur in reducing M. bovis counts
in the lung (39). These modest differences between studies may
simply reflect relatively small group sizes and variability in
sampling.
The identification of immunological correlates of protection
is essential to refine vaccine trials, to reduce the costs of chal-
lenge experiments, and to prioritize vaccine candidates enter-
ing efficacy trials. IFN- is an essential component of protec-
tive immune responses to M. bovis; vaccines which fail to prime
for the production of antigen-specific IFN- recall memory
responses invariably fail to protect against virulent challenge,
and in some studies, postvaccination levels of IFN- do corre-
late well with protection (reviewed in references 7, 18, and 22).
Here, both BCG Pasteur and BCG Danish induced strong
PPD-B-specific IFN- responses, but the overall level of IFN-
detected during the vaccination period did not correlate with
protective efficacy (r2  0.115). Interestingly, a previous study
(39) found that BCG Danish vaccination of calves induced
poor IFN- responses compared with BCG Pasteur vaccina-
tion, but this did not affect the protective immunity induced by
BCG Danish.
A number of studies have shown significant correlations
between protective immunity and cultured ELISPOT re-
sponses (9, 17, 30, 36). Although we have not shown defini-
tively for cattle that the cultured ELISPOT assay measures
only central memory, and not effector, T cell responses (due to
a lack of specific reagents for central memory T cells in cattle,
such as CCR7), a recent study revealed that PPD-specific cul-
tured ELISPOT responses in humans were principally those of
central memory T cells, as depletion of these cells ablated the
cultured ELISPOT response (30). As shown in other cattle
vaccine trials (36, 38), we demonstrated here that cultured
ELISPOT responses predict vaccine success and that the num-
ber of IFN--secreting memory T cells induced by vaccination
correlates with protective efficacy. Endsley et al. showed that
BCG vaccination of cattle induced memory CD4 T cell pop-
ulations with the capacity to kill infected macrophages (12)
that may play important roles in protective immunity against
virulent challenge, providing additional evidence that the qual-
ity of the CD4 T cell response induced by vaccination is a key
factor in vaccine success. Postchallenge, the number of anti-
gen-specific IFN--secreting effector CD4 T cells correlated
with the extent of disease, suggesting that this parameter can
be used as a surrogate or predictor of disease as well as vaccine
failure (29). Postchallenge IFN- measurements in whole
blood stimulated by either PPD-B or the M. bovis-specific
antigens ESAT-6 and CFP-10 also showed a correlation be-
tween extent of disease and IFN- levels. As demonstrated
previously, low levels of ESAT-6/CFP-10-specific IFN- were
detected in vaccinated/protected animals compared to the non-
vaccinated controls, and these responses are inverse correlates
of protection (20, 33). The responses to M. bovis-specific an-
tigens such as ESAT-6 and CFP10 are central to immunodi-
agnostic tests differentiating between infected and vaccinated
animals (DIVA) (4, 37).
In summary, we have shown that vaccination of neonatal
calves with either BCG Pasteur or BCG Danish significantly
reduces disease and bacterial load following challenge with M.
bovis. Furthermore, we provide additional evidence that mea-
surement of central memory T cells induced by vaccination can
predict vaccine success or failure. This adds to the accumulat-
ing body of evidence suggesting that BCG vaccination, either
alone or in prime-boost strategies, may be a useful tool for the
control of bovine tuberculosis.
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